JHL is uniquely positioned to deliver full-service contract manufacturing solutions to its worldwide partners, from cell line development through commercial Active Pharmaceutical Ingredient (API) manufacturing to international Good Manufacturing Practice (GMP) requirements.
Corporate Headquarter (Hsinchu, Taiwan)
JHL’s Headquarter is located in the newly opened Hsinchu Biomedical Science Park (HBSP) and houses the Corporate Administrative office, Process Development facilities, and Pilot and Clinical Manufacturing Plant. The headquarter utilizes a total of 2,000 ㎡ of the HBSP. Occupying approximately 38.1 hectares with easy access to major highways and the high speed rail, the HBSP is less than thirty minutes away from the Taoyuan International Airport, Taipei, and Taichung. Hsinchu is the oldest city in Northern Taiwan. With significant investment from the Taiwan government in infrastructure, Hsinchu is the high-tech hub of Taiwan, home to more than 350 high-tech companies.
JHL’s Process Development facilities have the capability for upstream process development, downstream process development, and analytical development. At the Process Development facilities, JHL is able to produce gram quantities in 5 to 50L bioreactors for use in proof of concept studies, stability evaluations, and other product characterization activities.
The Pilot and Clinical Manufacturing Plant was qualified for production in 1Q2014. The Plant have two 500L bioreactors and is capable of producing monoclonal antibodies in kilogram quantities for up to 20 products per year.
Research Center (Hsinchu, Taiwan)
JHL’s Research Facility is located in the newly opened Hsinchu Biomedical Science Park (HBSP).
Commercial GMP Facility (Wuhan, China)
Our commercial manufacturing facility will be located Wuhan National Bioindustry Base, commonly referred to as "Biolake. " Wuhan is the most populous city in inland China and is accessible by international airport and by high-speed rail from Beijing, Guangzhou, or Shanghai.
and technology transfer (process development) will all be based at this commercial GMP facility. The facility will include segregated upstream and down stream processing areas, segregated media buffer preparation and holding areas, and a two-suite purification area for pre-/post-viral processing and bulk filling. When operational, we will be capable of producing more than 100 kg of monoclonal antibodies per year in our single-use 2000L bioreactors.